Arcus Biosciences to Present New Data From Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by
BusinesswireApr 24 16:00 ET
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will
BusinesswireApr 23 16:05 ET
Express News | NYSE Order Imbalance 59853.0 Shares on Sell Side 59853.0 Shares on Sell Side
Moomoo 24/7Apr 18 15:50 ET
Express News | NYSE Order Imbalance 61111.0 Shares on Sell Side
Moomoo 24/7Apr 17 15:50 ET
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)
TipRanksApr 12 06:50 ET
Exelixis Slips as Barclays Downgrades on Lack of Catalysts
Seeking AlphaApr 11 10:10 ET
Top Buy-rated Stocks and Sell-rated Stocks Within Health Care - Citi
Seeking AlphaApr 4 11:12 ET
Investors Bid Arcus Biosciences (NYSE:RCUS) up US$219m Despite Increasing Losses YoY, Taking Five-year CAGR to 8.1%
Yahoo FinanceApr 1 06:15 ET
Insider Sell: COO Jennifer Jarrett Sells 11,551 Shares of Arcus Biosciences Inc (RCUS)
Yahoo FinanceMar 29 19:01 ET
Arcus Biosciences(RCUS.US) Officer Sells US$202.72K in Common Stock
$Arcus Biosciences(RCUS.US)$ Officer Jarrett Jennifer sold 11,551 shares of Common Stock on Mar 27, 2024 at an average price of $17.55 for a total value of $202.72K.Source: Announcement What is statem
moomoo NewsMar 29 17:02 ET
Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Dow JonesMar 26 16:35 ET
Express News | Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target
Moomoo 24/7Mar 25 11:54 ET
Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding
We'd be surprised if Arcus Biosciences, Inc. (NYSE:RCUS) shareholders haven't noticed that the Chief Operating Officer, Jennifer Jarrett, recently sold US$241k worth of stock at US$17.92 per share.
Simply Wall StMar 22 06:01 ET
Insider Sell: COO Jennifer Jarrett Sells 13,449 Shares of Arcus Biosciences Inc (RCUS)
Yahoo FinanceMar 20 19:00 ET
Investors Might Be Losing Patience for Arcus Biosciences' (NYSE:RCUS) Increasing Losses, as Stock Sheds 7.2% Over the Past Week
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. But Arcus
Simply Wall StMar 20 15:27 ET
Arcus Biosciences Insider Sold Shares Worth $543,187, According to a Recent SEC Filing
Juan C. Jaen, President, on February 26, 2024, sold 27,032 shares in Arcus Biosciences (RCUS) for $543,187. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,529,708 shares
MT NewswiresFeb 29 10:18 ET
Arcus Biosciences(RCUS.US) Officer Sells US$543.19K in Common Stocks
$Arcus Biosciences(RCUS.US)$ Officer Jaen Juan C. sold 27,032 shares of Common Stocks on Feb 26, 27, 2024 at an average price of $20.09 for a total value of $543.19K.Source: Announcement What is state
moomoo NewsFeb 28 20:37 ET
Arcus Biosciences(RCUS.US) Officer Sells US$1.18 Million in Common Stocks
$Arcus Biosciences(RCUS.US)$ Officer Jarrett Jennifer sold 58,625 shares of Common Stocks on Feb 26, 27, 2024 at an average price of $20.09 for a total value of $1.18 million.Source: Announcement What
moomoo NewsFeb 28 20:37 ET
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will
BusinesswireFeb 28 16:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the
BusinesswireFeb 27 16:35 ET
No Data
No Data